This study suggests a plant extract might boost ketone-body levels and reduce colitis-like inflammation in a mouse model — a concept that could inform future dietary or therapeutic research for ulcerative colitis but is...

The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.

The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.

Itch is a frequent, often severe symptom in PSC that is linked to liver disease severity and worse quality of life. Recognizing and measuring pruritus matters because it significantly affects daily functioning and may...

People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...

This preclinical study suggests a fox-derived Lactiplantibacillus plantarum strain can reduce inflammation and improve intestinal barrier markers in cell and mouse models of colitis, which could inform future...

The study links specific foods and combined dietary patterns with higher or lower odds of ulcerative colitis, which could inform patient conversations about diet and priorities for future research.

Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.

Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...

In young children, enteric infections can mimic or coexist with VEO‑IBD and change imaging and clinical findings; recognizing both can affect diagnosis and treatment choices.

An uncommon oropharyngeal mass due to Crohn’s disease can be diagnostically challenging and may not respond to corticosteroids or anti-TNF therapy. For some patients, switching to a different mechanism (here, a JAK...

Population estimates help patients understand how common IBD is and show that ulcerative colitis is more common than Crohn’s in this survey. Knowing prevalence and who is more likely to be diagnosed can help people feel...

Updated FDA prescribing information affects safety monitoring and counseling for people with ulcerative colitis who take mesalamine, including children meeting the weight threshold. The label highlights kidney monitoring...

Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.

This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...

Synthetic, severity-controlled endoscopic images could help researchers train and test IBD imaging algorithms and augment scarce labeled datasets, which may accelerate development of tools that interpret endoscopy for...

This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...

This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...

This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...

People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...

The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...

The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.

Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

Planned synthesis of global surgical rates and outcomes in the biologics era could help clinicians, patients, and researchers understand how often surgery is needed, what types of operations are performed, and common...

Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...

This study shows that people with IBD can display distinct self-care and illness-perception profiles rather than a single pattern; tailoring education and psychological support to these profiles could improve...

This work suggests a new way Crohn’s disease might begin: a weaker early immune response (linked to NOD2 gene defects) allows small intestinal infections to persist and later trigger the inflammation that causes...

Postoperative endoscopic recurrence after ileocolic resection is an important risk for people with Crohn’s disease; this study links HNBT and possibly e-cigarette use to higher recurrence rates, which could affect...

This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...

Timing of therapies and daily behaviors may affect drug metabolism, immune activity, and symptom patterns in IBD. Considering when treatments are given could potentially improve response, reduce toxicity, and help...

This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...

People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear...

Accurate measurement of physical activity matters because it’s linked to symptoms, fitness, and overall health.

The study describes a new ultrasound-activated nanozyme that reduced intestinal inflammation and promoted mucosal repair in preclinical IBD models by scavenging ROS and modulating the gut microbiota—an approach that...

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...

CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.

Individual factors like CYP2C9 genotype and liver impairment can raise etrasimod levels. The study’s model-based dose suggestions could help personalize dosing to reduce risk of excess exposure.

An FDA approval for an autoinjector of a biosimilar ustekinumab can make treatment easier to administer and may increase availability or affordability of a drug used to treat Crohn’s disease and ulcerative colitis....

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.

Accurate, reliable measurement of ulcers and polyps during endoscopy can improve disease assessment and tracking for people with Crohn’s disease and ulcerative colitis and may better align visual findings with symptoms...

A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.

This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.

Diagnosis between UC, Crohn’s disease, and unclassified IBD can change in a meaningful minority of patients over years. Awareness of common reasons for reclassification (segmental disease, strictures) helps guide...

Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...

Cure8 found this source from journals.lww.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.

An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...

Cure8 found this source from journals.lww.com, but the page could not be read reliably yet. It is tagged for Ileocecal Resection and Procedures and surgery. Open the original article for the full details.